Thinking of joining a study?

Register your interest

Become a volunteer?

NCT04426474 | COMPLETED | Diabetes Mellitus, Type 2

A Study of LY3502970 in Participants With Type 2 Diabetes
Sponsor:

Eli Lilly and Company

Brief Summary:

The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.

Condition or disease

Diabetes Mellitus, Type 2

Intervention/treatment

LY3502970

Placebo

Phase

PHASE1

Study Type : INTERVENTIONAL
Estimated Enrollment : 68 participants
Masking : DOUBLE
Primary Purpose : BASIC_SCIENCE
Official Title : A Multiple-Dose Study in Participants With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of LY3502970
Actual Study Start Date : 2020-10-08
Estimated Primary Completion Date : 2021-07-12
Estimated Study Completion Date : 2021-07-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Have type 2 diabetes mellitus (T2DM) for at least 6 months
  • * Have a glycated hemoglobin (HbA1c) value at screening of greater than or equal to (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening
  • * Have a body weight of ≥45 kilograms (kg) and have a body mass index of 18.5 to 45 kilograms per square meter (kg/m²), inclusive
  • * Have had a stable body weight for the 3 months prior to screening (less than \[\<\]5% body weight change)
  • * Males and females (not considered woman of childbearing potential)
Exclusion Criteria
  • * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
  • * Have had any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure
  • * Show evidence of hepatitis B, and/or positive hepatitis B surface antigen
  • * Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
  • * Any glucose-lowering medications other than metformin within 3 months prior to screening
A Study of LY3502970 in Participants With Type 2 Diabetes

Location Details

NCT04426474

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

United States, Florida

Clinical Pharmacology of Miami

Hialeah, florida, United States, 33014

Not yet recruiting

United States, New Jersey

Hassman Research Institute

Marlton, New Jersey, United States, 08053

Not yet recruiting

United States, Ohio

Midwest Clinical Research Unit

Dayton, Ohio, United States, 45417

Not yet recruiting

United States, Texas

Endeavor Clinical Trials

Saint Anthony, Texas, United States, 78229

Not yet recruiting

Germany, North Rhine-Westphalia

Profile Institute for Metabolism Research

Neuss, North Rhine-Westphalia, Germany, 41460

Not yet recruiting

Germany,

Profile Mainz

Mainz, Germany, 55116